Sapient

With the field of #multiomics evolving rapidly, particularly within the #proteomics space, you need 𝐓𝐡𝐞 𝐈𝐍𝐬𝐢𝐠𝐡𝐭 to keep pace. Our last newsletter of the year will be dropping soon, so if you are not yet #subscribed be sure to sign up to receive this coming edition. It will be complete with content on the latest applications of protein, metabolite, and lipid #biomarkers to advance drug development, including key discoveries and examples of how both discovery and targeted approaches are progressing sponsors' programs. Subscribe today: https://lnkd.in/gzZbWxQ6 #TheINsight #discovermore

Mo Jain traded academia to found Sapient, using mass spectrometry and AI to advance drug discovery. From physician to professor to entrepreneur, Mo’s journey is all about innovation in life science. Learn more in our November Member Spotlight: https://bit.ly/3YX9tLR

As investment in and approvals for GLP-1 therapies continue to accelerate, sponsors must ensure their development efforts can keep pace. Discovery #metabolomics can provide an unprecedented view into metabolic changes induced by GLP-1 agonists, revealing #biomarkers can be applied for: ➡️ Deepening #GLP1 mechanistic insights  ➡️ Patient stratification in GLP-1 agonist #clinicaltrials ➡️ Safety profiling of GLP-1 therapy ➡️ Expansion of GLP-1 agonist indications Learn more about how nontargeted profiling of dynamic biomarkers can uncover novel biological insights that drive greater competitive advantages. https://lnkd.in/gRqn_DGD

#Multiomics innovation was on display last week at Oxford Global's Multi-Omics in Biomarker Discovery & Precision Medicine Online Symposium! We thank all the speakers and delegates that joined us to share how they are integrating multi-omics technologies and techniques into therapeutic R&D. If you weren't able to make the live symposium, you can still watch Sapient's feature session, presented by Dr. Jonathan Usuka, here: https://lnkd.in/gHFYrBwZ

We're #hiring a new Business Development/Sr Business Development Director in San Diego Metropolitan Area. Apply today or share this post with your network.

#Hiring: We are seeking a highly motivated, detail-oriented 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐃𝐢𝐫𝐞𝐜𝐭𝐨𝐫 to join our growing commercial team. If you're interested in building long-lasting client relationships by empowering pharma and biotech sponsors with actionable insight to advance their drug programs successfully, #apply today: https://lnkd.in/gejM6iD9 #careers #businessdevelopment #BD #SapientTeam

"There are diseases in which the #genome does change—cancer being the prime example, as there are mutations that occur. But what about other diseases for which the genome is not changing? Heart disease, GI illness, liver disease, immunology and inflammatory diseases, fibrotic diseases, neurodegenerative diseases and renal disease are all examples with limited genetic influence. How do we begin to interrogate that? That is the basis of Sapient going #beyondthegenome, being able to understand the dynamic #biomarkers that can read out a person’s health, future disease risk, what drugs they’re going to respond to. This is information we're trying to capture to complement their underlying genomic risk score." Read more from Mo Jain, MD PhD's recent interview with Biocom California discussing the exciting strides being made in #multiomics technology to allow for large-scale discovery of dynamic #biomarkers. See how these protein, metabolite, and lipid markers are being applied in precision medicine programs today: https://lnkd.in/gc-YvD-m

We're #hiring a new Head of Proteomics in San Diego Metropolitan Area. Apply today or share this post with your network.

𝐖𝐞𝐥𝐜𝐨𝐦𝐞 Shaun Chen 𝐭𝐨 𝐒𝐚𝐩𝐢𝐞𝐧𝐭 𝐚𝐬 𝐃𝐚𝐭𝐚 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐬𝐭 𝐈𝐈! We are excited to share that Shaun has joined our data science team, bringing expertise in complex bioinformatics and machine learning/deep learning models to advance disease prevention and treatment. Shaun completed his PhD at The Scripps Research Institute, where he focused on developing ML frameworks for risk prediction and targeted interventions using biobank data integrated with multi-modal datasets and longitudinal electronic health records. He also earned his Master’s degree in Molecular and Cellular Biology from National Taiwan University. 📈 𝐌𝐚𝐤𝐢𝐧𝐠 𝐚𝐧 𝐢𝐦𝐩𝐚𝐜𝐭 On what drives him in his work, Shaun says it is the opportunity to contribute to research that improves health outcomes for individuals. “I've always been intrigued by the patterns in nature and biology—and the more I learned about the complexities of human health, the more passionate I became about using these insights to help prevent diseases through personalized medicine. I’m excited to collaborate with Sapient’s interdisciplinary team to apply cutting-edge models that transform multi-omics data into actionable healthcare solutions.” Please join us in welcoming Shaun to the #SapientTeam!

🧬𝐎𝐜𝐭𝐨𝐛𝐞𝐫 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧𝐬 & 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬 - 𝐩𝐚𝐫𝐭 𝟐🧬 MyOme & Broad Clinical Labs partner with Southern Research on 𝘾𝙖𝙩𝙖𝙡𝙮𝙨𝙩 program PacBio's short read sequencing instrument Onso™ instrument joins 10x Genomics compatible partner program PacBio & National Cancer Centre Singapore to study the genomics of prevalent cancers in Asia. Delve Bio & Broad Clinical Labs partner to improve access to metagenomic sequencing for neurological infections patients Myriad Genetics announced 5 research collaborations to study the use of the company's Precise MRD assay in breast cancer minimal residual disease monitoring. LGC Clinical Diagnostics & AccuGenomics partner to develop QC materials for NGS tests. Velsera & Diagnostica Longwood to accelerate the adoption of sequencing-based precision medicine in Spain & Portugal nextgen-dx.com & Shionogi & Co., Ltd to develop models for predicting microbial susceptibility to cefiderocol Codexis, Inc. inked a nonexclusive commercial and manufacturing license agreement for enzymes in its life science portfolio with Alphazyme LLC Owkin & AstraZeneca to develop an AI-based prescreening tool for gBRCA mutations in breast cancer. Seegene Inc. &Werfen to bring syndromic rtPCR testing to Spain Zymo Research Corp & BluMaiden Biosciences to provide clinical trial analytics & reporting services based on the human microbiome to pharmaceutical companies. Tempus AI strikes cancer drug research deal with JW Pharmaceutical Corporation Sapient partners with Rancho BioSciences to expand and refine its multiomics database. Caris Life Sciences & ECOG-ACRIN Cancer Research Group partner to analyze breast tumour samples from landmark TAILORx study. #collaboration #lifescience #biotech #genomics #proteomics #diagnostics #genetic #spatialomics